20 articles
New research shows combining weight-loss medications with hormone therapy could transform health outcomes for obese men with low testosterone.
The triple agonist retatrutide drives deep metabolic shifts beyond weight loss, improving key biomarkers of cardiovascular and insulin health.
The TRIUMPH program tests retatrutide across 5,800+ patients using a novel basket trial design to simultaneously tackle obesity and its complications.
Weekly tirzepatide injections led to up to 22% weight loss in Japanese participants, with 96-100% achieving clinically significant results.
Comprehensive review reveals estrogen-only therapy carries lower breast cancer risk than combined hormone treatments during menopause.
NIH study identifies metabolic mechanism behind controversial skin condition and demonstrates successful treatment with mitochondrial complex I inhibitors.
A Bayesian network meta-analysis of 19 RCTs finds retatrutide tops weight loss but dual agonists offer the best efficacy-safety balance.
Low-intensity resistance training with blood flow restriction improved muscle strength and mitochondrial function better than conventional exercise.
A landmark JCI review maps the expanding pharmacological arsenal for MASH, from GLP-1 agonists to triple receptor therapies and precision medicine.
FDA approval of the first T1D delay drug nearly doubled islet autoantibody testing, but critical gaps remain in screening healthy children.
Study finds both interpersonal therapy and health education help military teens improve weight and metabolic health outcomes.
Three months of romosozumab plus denosumab matched 12 months of romosozumab alone for bone strength gains in postmenopausal women.
A real-world study of 15,000+ patients finds tirzepatide outperforms both semaglutide and liraglutide in preventing major cardiac events.
A large real-world study finds post-transplant diabetes requiring insulin marks a high-risk metabolic phenotype with far worse graft and patient outcomes.
A 2025 mini-review synthesizes RCTs and meta-analyses showing hypertonic dextrose prolotherapy rivals or beats standard OA injections.
Comprehensive therapy combining Western medicine, traditional Chinese medicine, and lifestyle changes reversed diabetes in majority of patients.
New research reveals why Addison's disease patients face higher mortality despite treatment and explores promising therapeutic approaches.
Large NHANES study shows TyG-ABSI index better predicts cardiovascular disease and death in metabolic syndrome patients than standard measures.
Combined mitochondrial therapy restored muscle function and reduced fatigue in mouse model of Gulf War Illness.
A systematic review of 8 studies finds tirzepatide significantly reduces hsCRP and IL-6 across all doses and populations.
